SCReN is testing COMIRNATY vaccine in subjects received VAXZEVRIA

The condition is Covid19.

A new clinical trial is recruiting patients in the following locations: Spain.

The trial officially began on the April 24, 2021 and is planned to complete on April 30, 2022.

CombiVacS is a phase 2 randomized, adaptive trial developed to evaluate the immunogenicity of a dose of COMIRNATY after a previous single dose of VAXZEVRIA. A stratification will be made based on the following factors: study site, sex and age. This protocol allows to test the immunogenicity and safety of a heterologous vaccination strategy after a previous single dose of VAXZEVRIA.

Instituto de Salud Carlos III is the collaborator in this clinical trial.

The link to the complete study details, such as inclusion and exclusion criteria:

Clinical Research News

Upcoming Clinical Trials